New targeted drug shows promise for rare growth disorders

NCT ID NCT06975618

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 27 times

Summary

This study tests a new drug called CYH33 in people with rare conditions that cause abnormal growth of body parts or blood vessels. The drug targets a specific genetic change to help shrink overgrown tissue. The trial involves 141 adults and teens and will check for safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Capital Institute of Pediatrics

    RECRUITING

    Beijing, Beijing Municipality, 100000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Plastic Surgery Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100144, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shanghai Ninth People Hospital, Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200011, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.